NCT06863480View on ClinicalTrials.gov

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 30, 2028

Study Completion Date

October 30, 2028

Conditions
Aneurysmal Subarachnoid HemorrhageDelayed Cerebral Ischemia
Interventions
DRUG

tocilizumab-aazg (TYENNE)

A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.

Trial Locations (1)

32608

University of Florida Health (UF Health), Gainesville

All Listed Sponsors
lead

University of Florida

OTHER